Warfarin Versus Low Molecular Weight Heparin Therapy in Cancer Patients

Warfarin Versus Low Molecular Weight Heparin Therapy in Cancer Patients Leo R. Zacharski, Paolo Prandoni, Manuel Monreal Oncologist 2005; 10: 72-79 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Define characteristics of the interface between deep vein thrombosis and malignancy. Evaluate patient factors that may complicate long-term warfarin use in patients with cancer. List advantages that may be realized with low molecular weight heparin (versus warfarin) therapy in cancer patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 04, 2005 Most Recent Review: Jan. 04, 2005* Most Recent Update: Jan. 04, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.